8th RNAi-Based Therapeutics Summit

Memo

With major pharma investments, billion-dollar partnerships, and promising clinical progress launched the RNAi field into a new era of growth, there is a race to be the first to unveil the full potential of RNAi as a transformative therapeutic modality. Now, the biggest challenge for biopharma remains centred on optimizing delivery, as the industry strives to bring these innovative and life-changing RNAi therapies to wider patient populations. For 2027, the 8th RNAi-Based Therapeutics Summit returns to unite the leaders driving this momentum to explore the next frontier of RNAi development to overcome the challenge of extra-hepatic delivery across high-value indications like neurology, cardiometabolic disease, obesity, cardiovascular disease, and oncology and more. Providing the ultimate platform for RNAi drug developers to come together and work together in interactive workshops, hear from experts in panels, and explore new data from our expert speakers to accelerate the development of more potent and safer RNAi drugs. Join experts from Eli Lilly, Bayer, Canary Cure, Thalia Therapeutics and more to be part of the mission to usher in the future of RNAi therapeutics URLs:Tickets: https://go.evvnt.com/3866991-2?pid=5569Brochure: https://go.evvnt.com/3866991-3?pid=5569 Prices:Drug Developer Pricing - Conference + Workshop Day: USD 4507.00,Drug Developer Pricing - Conference Only: USD 3149.00,Academic Pricing - Conference + Workshop Day: USD 3907.00,Academic Pricing - Conference Only: USD 2749.00,Service Provider Pricing - Conference + Workshop Day: USD 5397.00,Service Provider Pricing - Conference Only: USD 3999.00 Speakers: Soren Ottosen, Senior Scientific Director, Bayer, Pooja Gangras, Director, Molecule Discovery and Technology Licensing, Eli Lilly, Jihye Park, Associate Director, Novo Nordsk, David Zebrowski, Founder and Chief Executive Officer, GenKardia, Michael Palfreyman, Non-Executive Director, Thalia Therapeutics, Jimmy Weterings, Vice President and Head of Oligonucleotide Therapeutics, Bonito Biosciences, Crystal Jin, Co-Founder and Chief Executive Officer, Bound Therapeutics, Paul Lawrence, Executive Director, Bioscience Research, Biocogent, Mark Barrett, Chief Business Officer, Madrigal Pharmaceuticals, Nicole Lykens, Co-Founder and Chief Technology Officer, Valaya Bio, Claudio Punzo, Co-Founder and Chief Scientific Officer, Trinetra Therapeutics, Raj Reddy, President, Founder and Chief Executive Officer, Canary Cure, David Solomon, Chief Executive Officer, Thalia Therapeutics, Thomas Ormsby, Postdoctoral Associate, UMass Chan Medical School, Julia Alterman, Assistant Professor, UMass Chan Medical School, David Jackson, Chief Executive Officer, Ceria Therapeutics, Katherine Palozola, Senior Principal Investigator, Aro Biotherapeutics, Marc Abrams, Chief Technology Officer, Sanegene Bio, Swetha Rajasekaran, Senior Scientist, Alltrna, Diego Piqueras-Losilla, Research and Development Project Leader, ARTHEx Biotech, Eamon Comer, Senior Director, Medicinal Chemistry, Judo Bio Category: Conferences | Science, Health and Medicine | Pharmaceuticals Date and Time: 27th January 2027 at 8:00 am to 29th January 2027 at 4:30 pm Venue details: Homewood Suites by Hilton Boston Seaport District, 670 Summer Street, Boston, Massachusetts, 02210, United States